All News
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
AI-assisted diagnosis for immunological disease
d
EurekAlert!
A novel machine learning framework – Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune disorders, viral infections, and vaccine responses with precision.
Read Article
CRP and Hidradenitis Supprativa
A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.
Read Article
Deucravacitinib in Psoriasis - 5 Year Outcomes
BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr.
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality.
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality. A new study suggests a risk prediction… https://t.co/v20ZCVZUQE https://t.co/GmWWQDpWUU
Dr. John Cush RheumNow ( View Tweet)
A common clinical phenotype arising from diverse pathogenic mechanisms. Study of PBMC transcriptomes (ACPA+ at-risk vs early ACPA+ RA vs controls). A TF signature was enriched in early RA & at-risk individuals (involving SUMOylation, RUNX2, YAP1, NOTCH3, β-Catenin). Cells w/… https://t.co/vCDEjIMXWa https://t.co/mizo7AXWvr
Dr. John Cush RheumNow ( View Tweet)
Australian population study of 14,041 RA pts (68% F; age 65 yrs) vs 33,785 controls, preexisting cancer (CA) in RA was less prevalent (7.6% vs 14.2%). Cancer incid. rates lower in RA (CIR 19.68 vs 24.77) & stable over 3 decades. RA CIR higher for lung (CIR 1.17) & heme CA (CIR… https://t.co/k5KRwYT6jl https://t.co/MVfmuTGlth
Dr. John Cush RheumNow ( View Tweet)
Three B-cell targeting anti-CD20 mAbs in clinical use:
- Rituximab (1997) for RA, GPA, CLL, NHL, Pemphigus Vulgaris
- Ofatumumab (2020) for relapsing MS
- Obinutuzumab (2013) for Follicular lymphoma & CLL
OFA & OBIN may be better than RTX in membranous GN pts w/ anti-RTX Abs… https://t.co/ZhUbXFXjSR https://t.co/vUHkS76PK7
Dr. John Cush RheumNow ( View Tweet)
At RWCS 2025, Dr. Susan Shenoi aptly noted the prevalence of multisystem inflammatory syndrome in children (MIS-C) has declined significantly. Does this indicated herd immunity or the decline of community SARS-CoV-2 (or both)? @ShenoiSusan https://t.co/vY01VDkNVl… https://t.co/c8Qu4OqBSh https://t.co/yZAoRcG6LN
Dr. John Cush RheumNow ( View Tweet)
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
https://t.co/ZsS3JOqdLh https://t.co/3JByNrLTGR
Links:
Dr. John Cush RheumNow ( View Tweet)
TULIP Extension trial shows #SLE Rx w/ anifrolumab + SOC had less organ damage after 208wks. 354 on ANIF (+SOC) vs 561 on SOC alone = ANIF was 59.9% lower SDI (SLE damage index) (HR 0.40) vs those on SOC alone at wk 208. https://t.co/Ox7efMsAW2 https://t.co/55jZBE2aTW
Dr. John Cush RheumNow ( View Tweet)
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/KpdY1MEM1w https://t.co/vETGMJgHf3
Dr. John Cush RheumNow ( View Tweet)
Livedoid vasculopathy (LV) is a rare chronic microvascular thrombosis dz w/ hypercoagulability and inflammation. Lit Search found 15 articles, 41 LV pts Rx w/ biologics & JAK inhib. 88% w/ positive responses & pain relief. TNFi were most used, then JAK inhibitors… https://t.co/3ugGdUlYcI https://t.co/0aXRKRi5RA
Dr. John Cush RheumNow ( View Tweet)
Korean insurance claims data shows #RA pts have a higher risk of renal cancer (vs gen. population), unrelated to serostatus. The renal CA risk (aHR 1.34;1.04–1.78) was higher in women (aHR 1.57); but RA was not assoc w/ risk of CA of bladder, prostate or testes… https://t.co/owSeqibcPu https://t.co/N3TRQuKZJs
Dr. John Cush RheumNow ( View Tweet)
Growing Physician Enthusiasm for AI in Healthcare
The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.
https://t.co/7nGn5XsfEI https://t.co/sH3yQtaQue
Dr. John Cush RheumNow ( View Tweet)
The Cartel is Coming for Rheumatology
At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.… https://t.co/nOllJFR9AQ https://t.co/IxyGaysOEe
Dr. John Cush RheumNow ( View Tweet)
Japanese study of 781 RA pts (78 dx w/ ILD; most UIP pattern). Mortality higher in RA-ILD (SMR 2.09) vs RA (1.16) vs gen population. Mortality increased w/ ILD (adj HR 2.97), advanced age (1.08/per yr) , and low BMI (3.07) https://t.co/EYKfHotZPr https://t.co/xC6E0OLfFs
Dr. John Cush RheumNow ( View Tweet)
Combination biologics in PsA: are we there yet?
Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush RheumNow ( View Tweet)
February 5, 2025, the FDA granted Fast Track designation to ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory class III or class IV lupus nephritis, & nd SLE with extrarenal Dz… https://t.co/ywXUTKSoB2 https://t.co/Es0F63MBrk
Dr. John Cush RheumNow ( View Tweet)